Examination of Pregabalin Access for Treatment of Indicated Pain Disorders: the ExPAND Study

Stopped early

Conditions studied: Fibromyalgia, Painful Diabetic Peripheral Neuropathy

In brief

The investigators hypothesize that fibromyalgia (FM) and painful diabetic peripheral neuropathy (pDPN) patients with access restrictions on pregabalin will lead to higher healthcare resource use and cost compared to patients without such restrictions on pregabalin in a naturalistic setting. The randomization will occur at the physician level and not the patient level.

Key facts

Study ID
NCT01280747
Run by
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
People needed
42
Starts
2011-01-01
Expected to finish
2012-04-01
Last updated by the study team
2021-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.